Sanofi SA (ADR) (SNY) Analysts See $0.78 EPS; 8 Analysts Bullish Paratek Pharmaceuticals (PRTK)

July 14, 2017 - By test

Among 9 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Paratek Pharmaceuticals had 16 analyst reports since July 23, 2015 according to SRatingsIntel. Leerink Swann reinitiated it with “Outperform” rating and $23 target in Thursday, October 27 report. Robert W. Baird initiated the shares of PRTK in report on Friday, May 13 with “Outperform” rating. The rating was upgraded by Zacks to “Hold” on Wednesday, September 2. The firm earned “Hold” rating on Tuesday, September 22 by Zacks. H.C. Wainwright maintained Paratek Pharmaceuticals Inc (NASDAQ:PRTK) on Friday, June 17 with “Buy” rating. The firm has “Hold” rating given on Saturday, August 8 by Zacks. Leerink Swann maintained the stock with “Buy” rating in Thursday, June 15 report. As per Friday, August 14, the company rating was upgraded by Zacks. As per Friday, June 17, the company rating was maintained by Ladenburg Thalmann. On Wednesday, June 21 the stock rating was maintained by Cantor Fitzgerald with “Buy”. See Paratek Pharmaceuticals Inc (NASDAQ:PRTK) latest ratings:

29/06/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0000 Maintain
21/06/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0000 Maintain
15/06/2017 Broker: Leerink Swann Rating: Buy New Target: $37.0000 Maintain
05/06/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $33.0000 Maintain
19/05/2017 Broker: Raymond James Rating: Strong Buy New Target: $36.00 Initiates Coverage On
04/04/2017 Broker: Wedbush Rating: Outperform Old Target: $30.00 New Target: $34.00 Maintain

Analysts expect Sanofi SA (ADR) (NYSE:SNY) to report $0.78 EPS on August, 4.They anticipate $0.04 EPS change or 5.41% from last quarter’s $0.74 EPS. SNY’s profit would be $1.95B giving it 15.48 P/E if the $0.78 EPS is correct. After having $0.76 EPS previously, Sanofi SA (ADR)’s analysts see 2.63% EPS growth. About 1.39M shares traded. Sanofi SA (ADR) (NYSE:SNY) has risen 26.96% since July 14, 2016 and is uptrending. It has outperformed by 10.26% the S&P500.

Among 10 analysts covering Sanofi-aventis Sa (NYSE:SNY), 3 have Buy rating, 1 Sell and 6 Hold. Therefore 30% are positive. Sanofi-aventis Sa had 16 analyst reports since October 15, 2015 according to SRatingsIntel. The firm has “Hold” rating by HSBC given on Tuesday, May 3. As per Friday, March 31, the company rating was maintained by JP Morgan. The rating was maintained by JP Morgan on Friday, April 21 with “Neutral”. On Thursday, October 15 the stock rating was upgraded by Morgan Stanley to “Overweight”. The company was downgraded on Friday, April 7 by HSBC. The firm earned “Underperform” rating on Thursday, December 10 by BNP Paribas. Goldman Sachs initiated the stock with “Neutral” rating in Monday, November 7 report. The stock of Sanofi SA (ADR) (NYSE:SNY) earned “Neutral” rating by JP Morgan on Wednesday, April 12. Bernstein downgraded Sanofi SA (ADR) (NYSE:SNY) on Monday, November 9 to “Mkt Perform” rating. Berenberg downgraded the shares of SNY in report on Thursday, May 11 to “Hold” rating.

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The company has market cap of $120.95 billion. The Company’s divisions are Pharmaceuticals, Human Vaccines , and Other. It has a 23.32 P/E ratio. The Pharmaceuticals segment comprises the commercial activities of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $673.38 million. The Firm is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. It currently has negative earnings. The Company’s product candidates are the antibacterials omadacycline and sarecycline.

Investors sentiment decreased to 1.22 in Q4 2016. Its down 0.61, from 1.83 in 2016Q3. It worsened, as 11 investors sold Paratek Pharmaceuticals Inc shares while 21 reduced holdings. 14 funds opened positions while 25 raised stakes. 14.91 million shares or 3.36% more from 14.42 million shares in 2016Q3 were reported. Retail Bank Of America De reported 0% in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Tiaa Cref Invest Management Lc holds 0% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 67,232 shares. Manufacturers Life Insur Company The has 0% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Alliancebernstein L P holds 0% or 12,200 shares in its portfolio. Moreover, Natl Bank Of New York Mellon Corporation has 0% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). California State Teachers Retirement invested in 37,722 shares. Susquehanna Grp Inc Llp stated it has 47,237 shares or 0% of all its holdings. Barclays Public Limited Company, a United Kingdom-based fund reported 10,110 shares. Grt Prtn Lc reported 0.12% stake. Blackrock Fund Advsrs holds 0% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 901,143 shares. Caxton Corporation has 1.15% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 21,923 shares. Bnp Paribas Arbitrage Sa holds 0% or 1,021 shares. Blackrock Advsrs Limited Company accumulated 9,218 shares or 0% of the stock. Granahan Inv Management Incorporated Ma holds 0.24% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK) for 455,230 shares. Credit Suisse Ag has 0% invested in Paratek Pharmaceuticals Inc (NASDAQ:PRTK).